The Oral Proteasome Inhibitor Ixazomib in Combination with Melphalan-Prednisone (MP) for Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 1/2 Dose-Escalation Study (NCT01335685)

Bortezomib-melphalan-prednisone (VMP) is a standard-of-care regimen for elderly NDMM patients. Whereas bortezomib is administered intravenously or subcutaneously, ixazomib is an oral proteasome inhibitor with a safety profile amenable to extended dosing.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Jesus San Miguel, Maria Asunci ón Echeveste Gutierrez, Ivan Špicka, María-Victoria Mateos, Kevin Song, Michael Craig, Joan Bladé, Roman Hájek, Christine Chen, Neeraj Gupta, Catriona Byrne, Vickie Lu, Helgi van de Velde, Sagar Lonial Source Type: research